OneCyte and Kemp Proteins to revolutionize cell line development
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
Subscribe To Our Newsletter & Stay Updated